Comparative Pharmacology
Head-to-head clinical analysis: LASMIDITAN versus RIMEGEPANT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LASMIDITAN versus RIMEGEPANT.
LASMIDITAN vs RIMEGEPANT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lasmiditan is a selective serotonin 5-HT1F receptor agonist. It acts centrally to inhibit trigeminal nerve activation and release of neuropeptides such as calcitonin gene-related peptide (CGRP), thereby aborting migraine pain without vasoconstriction.
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It blocks CGRP-mediated vasodilation and pain transmission in the trigeminovascular system.
50 mg or 100 mg orally as a single dose; may repeat after at least 2 hours if needed, not to exceed 200 mg in 24 hours.
75 mg orally as needed, maximum 75 mg in 24 hours; or 75 mg orally every other day for prevention.
None Documented
None Documented
Terminal elimination half-life: 5.7 hours (range 4-7 hours); supports BID dosing for acute treatment.
The terminal elimination half-life of rimegepant is approximately 11 hours. This supports once-daily oral dosing for acute migraine treatment, with steady-state reached within 7 days.
Primarily hepatic metabolism (CYP3A4); <1% excreted unchanged in urine; ~50% fecal elimination mainly as metabolites.
Rimegepant is eliminated primarily via hepatic metabolism (CYP3A4 and CYP2C9) and biliary/fecal excretion. Approximately 78% of the administered dose is recovered in feces (77% as parent drug and 1% as metabolites), and 24% is recovered in urine (0.5% as parent drug and 23.5% as metabolites).
Category C
Category C
CGRP Receptor Antagonist
CGRP Receptor Antagonist